D2301
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
What it measured
Main measures
The primary endpoint will be annualized relapse rate ( ARR) at 24 months, which is defined as the number of relapses per year.
Relapses
Who could take part
Relapsing MS
Inclusion: 1. Male and female patients aged 18-55 with a diagnosis of Multiple Sclerosis (2005 revised McDonald criteria). Exclusion: 1. Patients with a manifestation of MS other than RRMS.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To compare FTY720 1.25 mg and 0.5 mg with placebo and to demonstrate that at least the 1.25 mg FTY720 dose is superior to placebo as assessed by the annualised relapse rate in patients with RRMS treated for up to 24 months.
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
Started
Nov 2005
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error